Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that its drug candidate …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an update of its three …
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that it presented preclinical …
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today presents preclinical data on …
In a research report released today, MLV analyst Vernon Bernardino initiated coverage on shares of Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) with a Buy rating and …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Rexahn Pharmaceuticals (NYSE:RNN) with a $3 price target, following the company’s third-quarter results, posting EPS …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Rexahn Pharmaceuticals (NYSE:RNN) with a $3 price target, …
In a research report released July 18, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Rexahn Pharmaceuticals (RNN) with a $3 price target, …
